MyoKardia Inc.

MyoKardia Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
40.12 M
Public Float
25.85 M
MyoKardia Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.2
Market Cap
$2.27 B
Shares Outstanding
46.07 M
Public Float
37.89 M

Profile

Address
333 Allerton Avenue
San Francisco California 94080
United States
Employees -
Website http://www.myokardia.com
Updated 07/08/2019
MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.

Financials

View All
Created with Highcharts 5.0.14MyoKardia Inc.Net Income. Fiscal year is January-December. All values USD Thousands.12 70012 70016 82916 82922 94622 94613 15213 15245 95245 95267 69867 698201320142015201620172018020k40k60k80k
Created with Highcharts 5.0.14MyoKardia Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.005 9165 91614 19914 19939 19939 19922 50022 50033 55833 558201320142015201620172018010k20k30k40k50k

Anastasios E. Gianakakos
President, Chief Executive Officer & Director
David P. Meeker
Independent Director